Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.71 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.71 |
| ▸ | ITGAL | P20701 | 1/20 | 0.71 |
| ▸ | CA4 | P22748 | 1/20 | 0.71 |
| ▸ | CA6 | P23280 | 1/20 | 0.71 |
| ▸ | AHR | P35869 | 1/20 | 0.71 |
| ▸ | ADK | P55263 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indole SCHEMBL5205084 | 0.94 | TRPA1 (0.74) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL27631042 | 0.94 | TRPA1 (0.74) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL29160563 | 0.92 | TRPA1 (0.71) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL28479409 | 0.91 | TRPA1 (0.77) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL712897 | 0.90 | TRPA1 (0.68) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL28131517 | 0.89 | TRPA1 (0.74) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL2704553 | 0.89 | TRPA1 (0.74) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL28131513 | 0.89 | TRPA1 (0.74) | TRPA1CA1CA2ITGB2ICAM1 | |
| Indole SCHEMBL6386255 | 0.89 | AHR (0.90) | TRPA1CA1CA2ITGB2ICAM1 | |
| Benzamide SCHEMBL27844707 | 0.89 | TRPA1 (0.61) | TRPA1CA1CA2ITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1921856-A | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | claimed |
| JP-6128227-A | — | — | None | — | — | JP | disclosed |
| JP-6128227-A | — | — | None | — | — | JP | disclosed |
| CN-115715294-A | Method for synthesizing thioether-containing peptides | 海德堡医药研究有限责任公司 | 2023-02-24 | — | — | CN | disclosed |
| CN-109384702-A | A kind of preparation method of N- dithiocarbamate Benzazole compounds | 温州医科大学 | 2019-02-26 | — | — | CN | disclosed |
| CN-109069414-A | For treating the Igmesine of neurodegenerative disease | 西格马瑟拉公司 | 2018-12-21 | — | — | CN | disclosed |
| US-9353093-B2 | Indole-1-carboxamides as kinase inhibitors | ALLERGAN, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160096828-A1 | Indole-1-Carboxamides as Kinase Inhibitors | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| WO-2015088565-A1 | P2X4 RECEPTOR MODULATING COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-8101748-B2 | Fluorinated catharanthine derivatives, their preparation and their utilisation as Vinca dimeric alkaloid precursors | PIERRE FABRE MEDICAMENT (FR) | 2012-01-24 | — | — | US | disclosed |
| US-5965745-A | ASTHMA; ANTIARTHRITIC,-SHOCK AGENTS; BRONCHITIS; RESPIRATORY SYSTEM DISEASES, E.G. CHRONIC OBSTRUCTIVE AIRWAYS DISEASES; PSORIASIS; ALLERGIC RHINITIS; ATOPIC DERMATITIS | PFIZER INC (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0863873-A1 | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONISTS | PFIZER INC. (US) | 1998-09-16 | — | — | EP | disclosed |
| EP-0863873-A1 | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONISTS | PFIZER INC. (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1997013751-A1 | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONISTS | PFIZER INC. (US) | 1997-04-17 | — | — | WO | disclosed |
| WO-1997013751-A1 | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONISTS | PFIZER INC. (US) | 1997-04-17 | — | — | WO | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| US-5334597-A | Anti-asthmatic, antiallergic, antiinflammatory, cytoprotective treats angina, cerebral spasm, nephritis, hepatitis, uveitis, endotoxemia and allograft rejection | MERCK FROSST CANADA, INC. (CA) | 1994-08-02 | — | — | US | disclosed |
| JP-H06128227-A | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONIST | MERCK FROSST CANADA INC | 1994-05-10 | — | — | JP | disclosed |
| JP-H06128227-A | INDOLE CARBAMATES AS LEUKOTRIENE ANTAGONIST | MERCK FROSST CANADA INC | 1994-05-10 | — | — | JP | disclosed |
| EP-0538000-A1 | Indole and indazole carbamates as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096828-A1 | Indole-1-Carboxamides as Kinase Inhibitors | IGF1R, JAK2, REN | TRPA1 2197/4885CA1 4497/4885CA2 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.